1
|
Adamo V, Ricciardi GRR, Giuffrida D, Scandurra G, Russo A, Blasi L, Spadaro P, Iacono C, Soto Parra HJ, Savarino A, Ferraú F, Zerilli F, Verderame F, Butera A, Santangelo C, Franchina V, Caruso M. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. Ther Adv Med Oncol 2019; 11:1758835919895755. [PMID: 31903098 PMCID: PMC6923689 DOI: 10.1177/1758835919895755] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 11/15/2019] [Indexed: 11/15/2022] Open
Abstract
Background In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). Methods In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the median age was 58 years (range 29-79), with 69% of patients under 65. The median cycles of eribulin were 5.5 (range 1-26). The most common adverse event was neutropenia (9.3%, 3 cases of grade 3, 4 of grade 4); only 1 case of QT prolongation was reported. Eribulin was effective in controlling metastatic disease in all sites, and it achieved the highest ORR in brain (16%) and liver (14.9%). Median OS was 31.8 months (95% CI 27.9-34.4) and median PFS 5.5 months (95% CI 4.2-6.6). PFS was 5.2 months (95% CI 2.8-8.4) in patients with triple-negative subtype. Median PFS was longer in patients over 65 years (6.1 months, 95% CI 4.4-8.3). In patients who had visceral metastases PFS was 5.5 months (95% CI 95% 3.5-6.6) and OS 33.9 months (95% CI 29.8-40.8). Conclusions Eribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.
Collapse
Affiliation(s)
- Vincenzo Adamo
- Medical Oncology Unit A.O. Papardo and Department of Human Pathology University of Messina, Contrada Papardo, Messina, Italy
| | | | - Dario Giuffrida
- Department of Medical Oncology, Mediterranean Institute of Oncology, Viagrande, CT, Italy
| | | | - Antonio Russo
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Livio Blasi
- UOC Oncologia Medica, ARNAS Civico, Palermo, Piazza Nicola Leotta, Italy
| | - Pietro Spadaro
- U.O. di Oncologia ed Ematologia, Casa di Cura Villa Salus, Messina, Italy
| | - Carmelo Iacono
- Medical Oncology Department, Ospedale Maria Paterno Arezzo, Ragusa, Italy
| | - Hector J Soto Parra
- Medical Oncology Department, University Hospital Policlinico Vittorio Emanuele, Catania, Italy
| | - Antonino Savarino
- Unità Operativa di Oncologia, Ospedale "Barone Lombardo" di Canicattì, Contrada Giarre, Canicattì, AG, Italy
| | - Francesco Ferraú
- Medical Oncology Department, Ospedale S Vincenzo, Taormina, ME, Italy
| | | | | | | | | | - Veronica Franchina
- Medical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina, Contrada Papardo, Messina, Italy
| | | |
Collapse
|
2
|
Morritti M, Iodice G, Melaccio A, D'Onofrio L, Bergnolo P, Boglione A, Comandone A, Molinaro P, Garigliano D. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series. Future Oncol 2017; 13:25-33. [PMID: 28481183 DOI: 10.2217/fon-2016-0529] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
During the last decades, much effort has been made to develop and test treatments for advanced/metastatic breast cancer (MBC) able to prolong survival and improve patients' quality of life. In this regard, eribulin represents one of the most recent and interesting discoveries. This tubulin-targeting chemotherapy demonstrated a survival benefit in MBC women who progressed after at least two prior lines of chemotherapy for the treatment of metastatic disease (prior therapies should have included an anthracycline and a taxane, in either adjuvant or metastatic setting). Here, we described five cases of heavily pretreated MBC patients who experienced long-lasting control of disease with eribulin.
Collapse
Affiliation(s)
- Maria Morritti
- UO Oncologia, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - Giuseppe Iodice
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy
| | - Assunta Melaccio
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy
| | - Loretta D'Onofrio
- Oncologia Medica Policlinico Universitario 'Campus Bio-Medico di Roma', Roma, Italy
| | - Paola Bergnolo
- UOA di Oncologia, Ospedale Humanitas Gradenigo, Torino, Italy
| | | | | | | | | |
Collapse
|
3
|
Leo L, Caputo F, Sarno AD, Garofano T, Andreozzi F, Massaro MG, Montesarchio V. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report. Future Oncol 2015; 11:27-30. [DOI: 10.2217/fon.15.150] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
In this short paper, we report our experience with eribulin mesylate in a heavily pretreated breast cancer patient with multiple bone metastases. The patient had been treated with doxorubicin, cyclophosphamide, methotrexate, fluorouracil, tamoxifen, letrozole, LH-RH analogs, fulvestrant, bevacizumab and paclitaxel and liposomal doxorubicin. In November 2013 treatment with eribulin ready to use solution (1.23 mg/m2 days 1 and 8 of a 21-day cycle) was started and administered for a total of 14 courses. After six cycles of eribulin, evaluation with MRI showed a marked decrease in neoplastic involvement and replacement of osteolytic lesions with osteoblastic ones. No unexpected acute toxicity was observed. Although with all the limitations of any anecdotal report, our experience documents the efficacy and safety of eribulin in this difficult-to-treat patient who had been treated with multiple lines of chemotherapy.
Collapse
Affiliation(s)
- Luigi Leo
- Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy
| | | | | | | | | | | | | |
Collapse
|